Please assess the completion status of the following clinical trial:

Trial Title: Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal~* Greater than or equal to 45 years of age~* Osteopenia (lumbar spine bone mineral density \[BMD\] T-score between -1.0 and -2.5, and BMD T-score \> -2.5 at the femoral neck)~Exclusion Criteria:~* Patients with more than one Grade 1 vertebral fracture (as per Genant method; patients with one Grade 1 vertebral fracture are eligible to participate)~* Patients with any Grade 2 or 3 vertebral fracture (as per Genant method)~* Patients with 25-(OH) vitamin D levels less than 15 ng/mL prior to randomization~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zoledronic Acid 2x5 mg (Type: EXPERIMENTAL): Zoledronic acid 5 mg intravenous (i.v.) given at randomization and Month 12
- Zoledronic Acid 1x5 mg (Type: EXPERIMENTAL): Zoledronic acid 5 mg intravenous (i.v.) given at randomization and placebo at Month 12
- Placebo (Type: PLACEBO_COMPARATOR): Placebo given at randomization and Month 12

Based on this trial design, predict the completion outcome and termination type (if applicable).